Genome & Company (KOSDAQ:314130)

South Korea · Delayed Price · Currency is KRW

3,370.00

+85.00 (2.59%)

At close: Sep 9, 2026

Market Cap	176.25B +100.7%
Revenue (ttm)	24.46B +1.8%
Net Income	-41.36B
EPS	-1,179.43
Shares Out	52.30M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	92,230
Open	3,330.00
Previous Close	3,285.00
Day's Range	3,255.00 - 3,425.00
52-Week Range	2,470.00 - 10,180.00
Beta	0.38
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Genome & Company

Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea, Asia, Europe, South America, North America, and internationally. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors,... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Country South Korea

Stock Exchange KOSDAQ

Ticker Symbol 314130

Full Company Profile

Financial Performance

In 2025, Genome & Company's revenue was 24.59 billion, a decrease of -11.38% compared to the previous year's 27.74 billion. Losses were -6.43 billion, -68.04% less than in 2024.

Financial Statements